336 related articles for article (PubMed ID: 32189364)
81. Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression.
Lin CL; Chien RN; Chu YD; Liang KH; Huang YH; Ke PY; Lin KH; Lin YH; Yeh CT
Hepatol Int; 2020 Dec; 14(6):973-984. PubMed ID: 32770306
[TBL] [Abstract][Full Text] [Related]
82. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
[TBL] [Abstract][Full Text] [Related]
83. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
Hepatol Commun; 2021 Nov; 5(11):1873-1887. PubMed ID: 34558823
[TBL] [Abstract][Full Text] [Related]
84. rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.
Liu Y; Xu Z; Wang Y; Li X; Liu L; Chen L; Xin S; Xu D
PLoS One; 2014; 9(2):e89015. PubMed ID: 24586482
[TBL] [Abstract][Full Text] [Related]
85. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
[TBL] [Abstract][Full Text] [Related]
86. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
[TBL] [Abstract][Full Text] [Related]
87. Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Kim J; Lee SH; Kim HS; Choi K; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
Gut Liver; 2015 Jan; 9(1):103-8. PubMed ID: 25287170
[TBL] [Abstract][Full Text] [Related]
88. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
89. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.
Pollicino T; Raffa G; Santantonio T; Gaeta GB; Iannello G; Alibrandi A; Squadrito G; Cacciola I; Calvi C; Colucci G; Levrero M; Raimondo G
J Virol; 2011 Jan; 85(1):432-9. PubMed ID: 20962099
[TBL] [Abstract][Full Text] [Related]
90. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
[TBL] [Abstract][Full Text] [Related]
91. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
92. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients.
Takkenberg RB; Zaaijer HL; Molenkamp R; Menting S; Terpstra V; Weegink CJ; Dijkgraaf MG; Jansen PL; Reesink HW; Beld MG
J Med Virol; 2009 Jun; 81(6):988-95. PubMed ID: 19382261
[TBL] [Abstract][Full Text] [Related]
93. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
[TBL] [Abstract][Full Text] [Related]
94. Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
Margeridon-Thermet S; Svarovskaia ES; Babrzadeh F; Martin R; Liu TF; Pacold M; Reuman EC; Holmes SP; Borroto-Esoda K; Shafer RW
Antimicrob Agents Chemother; 2013 Jan; 57(1):343-9. PubMed ID: 23114756
[TBL] [Abstract][Full Text] [Related]
95. Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection.
Larsson SB; Malmström S; Hannoun C; Norkrans G; Lindh M
Virol J; 2015 Dec; 12():213. PubMed ID: 26645241
[TBL] [Abstract][Full Text] [Related]
96. Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients.
Singla B; Chakraborti A; Sharma BK; Kapil S; Chawla YK; Arora SK; Das A; Dhiman RK; Duseja A
Mol Biol Rep; 2014 Jul; 41(7):4689-96. PubMed ID: 24706057
[TBL] [Abstract][Full Text] [Related]
97. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
98. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
99. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation.
Fung J; Wong T; Chok K; Chan A; Sin SL; Cheung TT; Dai WC; Ng K; Ng K; Man K; Seto WK; Lai CL; Yuen MF; Lo CM
Transplantation; 2017 Oct; 101(10):2391-2398. PubMed ID: 28731907
[TBL] [Abstract][Full Text] [Related]
100. Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B.
Chi XM; Wang XM; Wang ZF; Wu RH; Gao XZ; Xu HQ; Ding YH; Niu JQ
World J Gastroenterol; 2021 Oct; 27(40):6927-6938. PubMed ID: 34790015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
